Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. 1993

S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
Division of General Internal Medicine, University of Texas Southwestern Medical School, Dallas 75235-9103.

TLC G-65, a liposome-encapsulated gentamicin, was given intravenously twice weekly for 4 weeks to AIDS patients with Mycobacterium avium-M. intracellulare complex (MAC) bacteremia at 1.7 mg of gentamicin per kg of body weight per infusion (4 patients), 3.4 mg/kg (10 patients), and 5.1 mg/kg (7 patients). MAC colony counts in blood fell by 75% or more in all three groups (P < 0.005). Drug resistance did not emerge during the study period. Transient renal insufficiency developed in one patient; no other adverse effects were detected. Liposome-encapsulated gentamicin is a potential therapy for MAC infections in AIDS patients.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015169 Colony Count, Microbial Enumeration by direct count of viable, isolated bacterial, archaeal, or fungal CELLS or SPORES capable of growth on solid CULTURE MEDIA. The method is used routinely by environmental microbiologists for quantifying organisms in AIR; FOOD; and WATER; by clinicians for measuring patients' microbial load; and in antimicrobial drug testing. Agar Dilution Count,Colony-Forming Units Assay, Microbial,Fungal Count,Pour Plate Count,Spore Count,Spread Plate Count,Streak Plate Count,Colony Forming Units Assay, Microbial,Colony Forming Units Assays, Microbial,Agar Dilution Counts,Colony Counts, Microbial,Count, Agar Dilution,Count, Fungal,Count, Microbial Colony,Count, Pour Plate,Count, Spore,Count, Spread Plate,Count, Streak Plate,Counts, Agar Dilution,Counts, Fungal,Counts, Microbial Colony,Counts, Pour Plate,Counts, Spore,Counts, Spread Plate,Counts, Streak Plate,Dilution Count, Agar,Dilution Counts, Agar,Fungal Counts,Microbial Colony Count,Microbial Colony Counts,Pour Plate Counts,Spore Counts,Spread Plate Counts,Streak Plate Counts

Related Publications

S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
June 1990, Antimicrobial agents and chemotherapy,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
April 1990, The Journal of infectious diseases,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
July 1990, The Journal of infectious diseases,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
November 1991, Lancet (London, England),
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
March 1994, Antimicrobial agents and chemotherapy,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
September 1988, Antimicrobial agents and chemotherapy,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
July 1992, Antimicrobial agents and chemotherapy,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
December 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
July 1991, The Journal of infectious diseases,
S D Nightingale, and S L Saletan, and C E Swenson, and A J Lawrence, and D A Watson, and F G Pilkiewicz, and E G Silverman, and S X Cal
June 1992, The Journal of infectious diseases,
Copied contents to your clipboard!